Apoptosis and frequency of total and effector CD8+ T lymphocytes from cutaneous leishmaniasis patients during antimonial therapy
Adult
Male
0301 basic medicine
Meglumine Antimoniate
Antiprotozoal Agents
Leishmaniasis, Cutaneous
Antigens, Protozoan
Apoptosis
CD8-Positive T-Lymphocytes
Middle Aged
Flow Cytometry
Leishmania braziliensis
3. Good health
Cohort Studies
Young Adult
03 medical and health sciences
Infectious Diseases
Meglumine
Organometallic Compounds
Humans
Female
Brazil
Research Article
DOI:
10.1186/s12879-015-0799-x
Publication Date:
2015-02-17T23:58:35Z
AUTHORS (10)
ABSTRACT
Leishmaniasis is an important parasitic disease affecting millions worldwide. Human cutaneous leishmaniasis (CL) endemic in Rio de Janeiro, Brazil, where caused by Leishmania braziliensis. The adaptive immune response accountable for the healing of CL and despite key role CD8+ T cells this little known about lymphocytes frequencies, apoptosis antigen-responsive patients during antimonial therapy.Using flow cytometry, we examined total effector from before (PBT), (PDT) after (PAT) treatment frequencies upon isolation vitro L. braziliensis antigens (LbAg)-stimulation culture. Besides, a correlation study between immunological findings lesion size was done.PDT showed lower higher levels these cells, which were also observed following LbAg-stimulation Regarding high PDT, while PAT. Interestingly, PDT apoptotic-effector lymphocytes. Similar results seen antigenic-stimulation assays. Correlation analysis that greater lesion, smaller frequency PAT, as well positive PDT.Changes T-lymphocyte treatment, seem to represent critical stage generate efficient suggest would be evolved triggering or resolution under influence therapy. This hypothesis opens new perspectives clarify controversial statements protective deleterious cure aggravation approach evaluating proved utmost importance understanding process human CL.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (38)
CITATIONS (12)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....